Article

Allergan receives approvable letter for glaucoma drug

The FDA issued an approvable letter to Allergan Inc. that will allow additional clinical investigation of the company's timolol combination product, bimatoprost 0.03%/timolol 0.05% ophthalmic solution (Lumigan), for glaucoma.

The FDA issued an approvable letter to Allergan Inc. that will allow additional clinical investigation of the company's timolol combination product, bimatoprost 0.03%/timolol 0.05% ophthalmic solution (Lumigan), for glaucoma.

An approvable letter sets out the conditions that a company must meet in order to obtain FDA final marketing approval.

"The FDA's response necessitates additional clinical investigation," said Scott Whitcup, MD, executive vice president, research and development, Allergan, in a company statement. "Allergan has already initiated an additional clinical study that we currently anticipate will be completed by the end of 2004."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.